ReviewViruses2022
Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Predictive value of epigenetic circulating free DNA (cfDNA) typing for cardiac function stratification in patients with cardiovascular disease.American journal of translational research · 2026Article
- Prospective observational study of cell-free DNA as a prognostic biomarker in COVID-19 and bacterial sepsis: COVSEP-study.Scientific reports · 2025Observational
- Extracellular DNA, hyaluronic acid, HIF pathways, and LncRNAs as predictive biomarkers of severe COVID-19.Virology journal · 2025Review
- Battle of the Biomarkers of Systemic Inflammation.Biology · 2025Review
- Increased levels of circulating cell-free DNA in COVID-19 patients with respiratory failure.Scientific reports · 2024Article
- The Diagnostic, Prognostic, and Therapeutic Potential of Cell-Free DNA with a Special Focus on COVID-19 and Other Viral Infections.International journal of molecular sciences · 2023Review
- Plasma cfDNA predictors of established bacteraemic infection.Access microbiology · 2022Article
- Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19.Scientific reports · 2022Article
- Integrating plasma cell-free DNA with clinical laboratory results enhances the prediction of critically ill patients with COVID-19 at hospital admission.Clinical and translational medicine · 2022Article
- Using Precision Medicine for the Diagnosis and Treatment of Viral Pneumonia.Advances in therapy · 2022Review
- Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19.Molecular biomedicine · 2022Review
- Utility of Monocyte Expression of HLA-DR versus T Lymphocyte Frequency in the Assessment of COVID-19 Outcome.International journal of general medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
WHO has declared COVID-19 as a worldwide, public health emergency. The elderly, pregnant women, and people with associated co-morbidities, including pulmonary disease, heart failure, diabetes, and cancer are the most predisposed population groups to infection. Cell-free DNA is a very commonly applied marker, which is elevated in various pathological conditions. However, it has a much higher sensitivity than standard biochemical markers. cfDNA appears to be an effective marker of COVID-19 complications, and also serves as a marker of certain underlying health conditions and risk factors of severe illness during COVID-19 infection. We aimed to present the possible mechanisms and sources of cfDNA released during moderate and severe infections. Moreover, we attempt to verify how efficiently cfDNA increase could be applied in COVID-19 risk assessment and how it corresponds with epidemiological data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.